340B After Genesis and Other Recent Developments: Definition of Patient, Registration of Child Sites, and Contract Pharmacy Use

Active

Program Number

34148

Program Date

2024-08-19

CLE Credits

While many 340B stakeholders hoped last year’s federal court decision in the Genesis case regarding the definition of a 340B-eligible “patient” would resolve ongoing uncertainty about when 340B covered entities can use discounted drugs purchased through the federal 340B Program, there has been a constant flow of 340B Program developments in the months since the decision and continued uncertainty for stakeholders.

This webinar will cover key evolving issues of importance to 340B covered entities, as well as other companies operating in the 340B space, including the current status of the definition of a 340B-eligible “patient,” ongoing litigation related to the use of 340B drugs in hospital “child sites” and through contract pharmacies, and recent legislative developments at the federal and state levels.

Attorneys participating in this webinar will gain the necessary knowledge to answer the following questions:

How is the Health Resources and Services Administration (HRSA) applying the definition of “patient” in audits of covered entities?
What is the current status of state efforts to regulate 340B contract pharmacy arrangements?
How many drug manufacturers are imposing restrictions on sales of 340B drugs for dispensing through contract pharmacy arrangements and what do those restrictions do?
What is the current status of litigation related to the use of 340B drugs in hospital “child sites”?
What changes to the 340B Program would be implemented if pending federal legislation were passed and enacted?